Key result
Active cancer in patients undergoing TAVR was associated with significantly higher 1-year all-cause mortality compared to those without cancer (RR 1.71; 95% CI 1.26-2.33; p=0.0006).
Why the study?
Patients with severe aortic stenosis and active cancer are considered high risk and typically ineligible for surgical replacement, but little is known regarding TAVR outcomes in this population.
Does TAVR in patients with severe aortic stenosis and active cancer result in similar mortality and safety outcomes compared to patients without active cancer?
Comparison
TAVR in patients with active cancer vs without active cancer
Design
Systematic review and meta-analysis
Follow-up
1-year follow-up
Authors
Loading...
TAVR may be feasible in select patients with severe AS and active cancer; leaves open need for prospective trials before broader adoption.
Meta-Analysis (n=5,162)
Does TAVR in patients with severe aortic stenosis and active cancer result in similar mortality and safety outcomes compared to patients without active cancer?
Relative Risk: 1.71 (95% CI 1.26–2.33)
p-value: p=0.0006
TAVR in patients with severe aortic stenosis and active cancer is associated with similar 30-day mortality but higher 1-year mortality compared to those without cancer, with the 1-year risk dependent on cancer stage.
Bendary et al. (2020) conducted a meta-analysis in Severe aortic stenosis (n=5,162). Active cancer vs. No active cancer was evaluated on All-cause mortality at 1-year follow-up (RR 1.71, 95% CI 1.26 to 2.33, p=0.0006). Active cancer in patients undergoing TAVR was associated with significantly higher 1-year all-cause mortality compared to those without cancer (RR 1.71; 95% CI 1.26-2.33; p=0.0006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: